Steinberg E P, Tunis S, Shapiro D
Johns Hopkins School of Medicine, USA.
Health Aff (Millwood). 1995 Winter;14(4):143-58. doi: 10.1377/hlthaff.14.4.143.
As the number and cost of new technologies grow, it is increasingly important that we develop sound policies for payment for those technologies while their clinical impacts are being defined. Such policies need to balance social interests in promotion of innovation, early access to promising technology, patient safety, control of health care costs, and return on investment. We present a rationale, policy options, and a proposal for insurance coverage of experimental technology.
随着新技术的数量和成本不断增加，在确定这些技术的临床影响时，制定合理的技术支付政策变得越来越重要。此类政策需要在促进创新、尽早获得有前景的技术、患者安全、控制医疗成本以及投资回报等社会利益之间取得平衡。我们提出了一个基本原理、政策选项以及一项关于实验性技术保险覆盖范围的建议。
